Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2157-2164

  Alfonso, Ana ^a   Redondo, Margarita ^b   Rubio, Tomás ^b   Del Olmo, Beatriz ^c,d   Rodríguez Wilhelmi, Pablo ^b   García Velloso, María J ^a   Richter, José A ^a   Páramo, José A ^a   Lecumberri, Ramõn ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

^c Hospital San Juan di Dios   (Spain)

^d Blood and Tissues Bank of Navarra   (Spain)

Author keywords

FDG PET CT; occult cancer; screening; tissue factor; venous thromboembolism

Indexed keywords

ANTIVITAMIN K; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; THROMBOPLASTIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; COLON ADENOCARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST CONTROL; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE COST; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OCCULT CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT SELECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SENSITIVITY AND SPECIFICITY; SURVIVAL; THYROID CARCINOMA; VENOUS THROMBOEMBOLISM;

FDG-PET/CT; OCCULT CANCER; SCREENING; TISSUE FACTOR; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; EARLY DETECTION OF CANCER; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASMS, UNKNOWN PRIMARY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; VENOUS THROMBOEMBOLISM;

EID: 84882713389     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28229     Document Type: Article

References (28)

1. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-91.
2. Lecumberri R, Páramo JA, Rocha E,. Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies. Haematologica 2005; 90: 1258-66.
3. Young A, Chapman O, Connor C, et al. Thrombosis and cancer. Nat Rev Clin Oncol 2012; 9: 437-49.
4. Trujillo-Santos J, Prandoni P, Rivron-Guillot K, et al. Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost 2008; 6: 251-5.
5. Sørensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-73.
6. Sørensen HT, Sværke C, Farkas DK, et al. Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer 2012; 48: 586-93.
7. Rosovsky R, Lee AY,. Evidence-based mini-review: should all patients with idiopathic venous thromboembolic events be screened extensively for occult malignancy? Hematology Am Soc Hematol Educ Program 2010; 2010: 150-2.
8. Monreal M, Lensing AW, Prins MH, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2004; 2: 876-81.
9. Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 2: 884-9.
10. Jara-Palomares L, Rodríguez-Matute C, Elías- Hernández T, et al. Testing for occult cancer in patients with pulmonary embolism: results from a screening program and a two-year follow-up survey. Thromb Res 2010; 125: 29-33.
11. Rieu V, Chanier S, Philippe P, et al. Systematic screening for occult cancer in elderly patients with venous thromboembolism: a prospective study. Intern Med J 2011; 41: 769-75.
12. Van Doormaal FF, Terpstra W, Van Der Griend R, et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost 2011; 9: 79-84.
13. Kubota K,. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001; 15: 471-86.
14. Delgado-Bolton RC, Fernández-Pérez C, González- Maté A, et al. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003; 44: 1301-14.
15. Sharma P, Kumar R, Jeph S, et al. 18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus? Nucl Med Commun 2011; 32: 782-8.
16. Rondina MT, Wanner N, Pendleton RC, et al. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. Thromb Res 2012; 129: 22-7.
17. Khorana AA, Connolly GC,. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839-47.
18. Ay C, Pabinger I,. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res 2012; 129 (Suppl 1): S6-S9.
19. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10: 1363-70.
20. Lecumberri R, Pegenaute C, Páramo JA,. Clinical use of D-dimer in patients with cancer. Med Clin (Barc) 2011; 137: 453-8.
21. RESOLUCIÓN 882/2010, de 3 de mayo, del Director Gerente del Servicio Navarro de Salud-Osasunbidea, por la que se actualizan las tarifas por prestaciõn de servicios en los centros y establecimientos asistenciales del Servicio Navarro de Salud-Osasunbidea. BON. Boletín Oficial de Navarra núm. 71, 11 de Junio de 2010. Available at: http://bon.vlex.es/ vid/actualizan-establecimientos-asistenciales-207649811.
22. Carrier M, Le Gal G, Wells PS, et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 2008; 149: 323-33.
23. DI Nisio M, Otten HM, Piccioli A, et al. Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost 2005; 3: 2391-6.
24. Schöder H, Gönen M,. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 2007; 48 (Suppl 1): 4S-18S.
25. Wagner JL,. Cost-effectiveness of screening for common cancers. Cancer Metastasis Rev 1997; 16: 281-94.
26. Kasthuri RS, Taubman MB, Mackman N,. Role of tissue factor in cancer. J Clin Oncol 2009; 27: 4834-8.
27. Cosmi B, Legnani C, Tosetto A, et al. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. J Thromb Thrombolysis 2009; 28: 381-8.
28. Schutgens RE, Beckers MM, Haas FJ, et al. The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 2005; 90: 214-19.